MAPT and Alzheimer disease: Relatedly, greater hippocampal atrophy over a three-year period has been reported in Met carriers who had higher levels of AD-related pathology [65], and, in autosomal-dominant AD, Met carriers have significantly worse memory performance, lower hippocampal metabolism and increased levels of pathological tau [68].